PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE

February 14, 2001

Slides

Intramuscular Olanzapine (NDA 21-253) for the Rapid Control of Agitation, Eli Lilly and Company

Disclaimer

The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Slides   ppt   html

Additional Slides   ppt   html